Extensive work in pre-clinical models of diseases such as retinal detachment [7–10], age-related macular degeneration (AMD) [11, 12], and glaucoma [6, 13] has shown that Fas is highly upregulated in these conditions and that inhibiting the activation of the Fas receptor leads to retinal protection. Here, FAS is linked to age-related macular degeneration.